Adicet Bio completed the final patient visit for its planned prula-cel analysis in systemic lupus erythematosus, with topline results expected in September 2026. The update also sets out clinical progress for ADI-212 in metastatic castration-resistant prostate cancer and a longer-term in vivo CAR-T development plan.

Key Highlights

  • Adicet Bio expects to discuss prula-cel results and subsequent program steps during an investor webcast.
  • The FDA cleared ADI-212 for study in metastatic castration-resistant prostate cancer, with enrollment planned in the fourth quarter of 2026.
  • Adicet Bio expects to release topline prula-cel data in September 2026.

Adicet Bio, Inc. (NASDAQ: ACET) completed the final patient visit for a planned analysis of prulacabtagene leucel, known as prula-cel, in systemic lupus erythematosus patients with or without lupus nephritis. Topline results are expected in September 2026, followed by an investor webcast covering the results and next steps. The update also outlines progress across Adicet’s autoimmune and oncology programs. Its systemic sclerosis program is expected to provide a clinical update in the fourth quarter of 2026, while the company has begun start-up activities for an ADI-212 clinical study after FDA clearance of the candidate’s Investigational New Drug application.

The planned prula-cel analysis covers SLE patients with or without LN and includes follow-up data from the study population. Adicet said it is developing a potential registrational trial design after discussions with the FDA, with more information expected during the upcoming clinical update.

ADI-212 and In Vivo CAR-T Programs Advance

The FDA cleared ADI-212 in August 2026 for patients with metastatic castration-resistant prostate cancer. Adicet describes the candidate as a gene-edited, armored, off-the-shelf cell therapy designed with multiple platform enhancements, including expression of an immune-stimulating molecule.

Peers Moving on This News